Latest news with #BiovelocitaII
Yahoo
18-03-2025
- Business
- Yahoo
Sofinnova Partners and Gustave Roussy launch first biotech company through Strategic Partnership
Signadori Bio, a novel cell therapy platform, emerges from collaboration with scientific founders Dr. Jean-Luc Perfettini and Professor Nathalie Chaput PARIS, March 18, 2025--(BUSINESS WIRE)--Sofinnova Partners, a leading European life sciences venture capital firm, in collaboration with Gustave Roussy, Europe's leading cancer center, announces the creation of their first pioneering biotech company. Signadori Bio, developed with scientific founders Dr. Jean-Luc Perfettini and Professor Nathalie Chaput, is a breakthrough cell therapy platform focused on transforming cancer treatment. This milestone marks a significant achievement in their strategic partnership, aimed at accelerating biotech innovation through rigorous evaluation and development of scientific research. Since the partnership's inception in 2023, it has rigorously evaluated 50 promising projects. This has culminated in the creation of a groundbreaking biotech venture in the cell and gene space that is set to advance innovative approaches in oncology. More information will be released as the company comes out of stealth later this year. Additionally, several other promising projects are in the pipeline, showcasing the immense potential for future breakthroughs in cancer therapeutics. "With cancer on the rise, particularly among younger populations, it's critical that we fast-track the most promising scientific breakthroughs into tomorrow's treatments. This partnership is a powerful example of how academia and investors can work together to drive innovation through new companies," said Professor Fabrice Barlesi, General Director of Gustave Roussy. "Gustave Roussy is at the forefront of cancer discovery. With Sofinnova's expertise in company creation, we are now able to quickly translate these innovations into real-world therapies to benefit patients worldwide." Matthieu Coutet, Partner at Sofinnova Partners and CEO of Signadori Bio, added: "Turning cutting-edge research into biotech success stories requires more than financing or scientific excellence—it demands the right ecosystem. By combining Gustave Roussy's research power with Sofinnova's proven ability to build and scale biotech ventures, we're creating a direct path from lab to the clinic." As these ventures progress, Sofinnova Partners and its academic collaborators remain committed to fostering the next generation of biotech companies and driving innovation in cancer therapeutics. This groundbreaking initiative, supported by Sofinnova's Biovelocita II—a €165M biotech acceleration fund dedicated to identifying and developing cutting-edge scientific advancements from top institutes like Gustave Roussy. This effort is undertaken in close collaboration with the institute's technology transfer office, Gustave Roussy Transfert. About Sofinnova Partners Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners manages over €4 billion in assets. For more information, please visit: About Gustave Roussy Ranked by Newsweek magazine as the leading European Cancer Centre and fourth in the world, Gustave Roussy is a centre with comprehensive expertise and is devoted entirely to patients suffering with cancer. The Institute is a founding member of the Paris-Saclay Cancer Cluster. It is a source of diagnostic and therapeutic advances. It caters for almost 50,000 patients per year, including 3,500 children and adolescents, and its approach is one that integrates research, patient care and teaching. It is specialized in the treatment of rare cancers and complex tumors and it treats all cancers in patients of any age. Its care is personalized and combines the most advanced medical methods with an appreciation of the patient's human requirements. In addition to the quality of treatment offered, the physical, psychological and social aspects of the patient's life are respected. 4,100 professionals work on its two campuses: Villejuif and Chevilly-Larue. Gustave Roussy brings together the skills that are essential for the highest quality research in oncology: 40% of patients treated are included in clinical studies. For further information: About Gustave Roussy Transfert Created in 2000, Gustave Roussy Transfert is Gustave Roussy's subsidiary dedicated to the development and transfer of technologies. Its missions are (1) to create and identify innovations from all the research teams based at Gustave Roussy, (2) to set up and monitor translational partnerships involving Gustave Roussy, and (3) to source, promote and support Gustave Roussy's entrepreneurial projects. Gustave Roussy and Sofinnova Partners announce the creation of a pioneering biotech company and unveil several promising projects. View source version on Contacts Sofinnova Partners Bommy Lee Head of Communicationsblee@ +33 (0) 6 47 71 38 11Gustave Roussy Claire Parisel +33 (0) 6 17 66 00 26Media inquiries: United Kingdom Optimum Strategic CommunicationsHana Maliksofinnova@ +44 (0) 20 3922 0900France Strategies&Image (S&I)Anne +33 (0) 6 03 35 92 05Italy Havas PR MilanPierluigi +39 (0) 392 77 999 33 Sign in to access your portfolio
Yahoo
18-03-2025
- Business
- Yahoo
Forth Tx Launches With Backing From Sofinnova Partners to Revolutionize Fibrosis Treatments
Cutting-edge research from Professor Neil Henderson at the University of Edinburgh Led by CEO Alex Leech, Partner at Sofinnova Partners Created through Sofinnova's €165M Biovelocita II, biotech fund EDINBURGH, Scotland & CAMBRIDGE, England, March 18, 2025--(BUSINESS WIRE)--Forth Therapeutics (Forth Tx), a biotechnology company advancing next-generation precision therapeutics for fibrosis, launches today with backing from Sofinnova Partners, a leading European life sciences venture capital firm, alongside Old College Capital (OCC), the University of Edinburgh's in-house venture investment fund. Headquartered in Edinburgh and Cambridge, Forth Tx builds on pioneering research from Professor Neil Henderson, a world-renowned fibrosis and tissue regeneration expert. The company spun out of the University of Edinburgh and is led by CEO Alex Leech, a serial entrepreneur and Partner at Sofinnova Partners, who brings decades of company-building expertise. The company's precision therapeutics platform focuses on tackling fibrosis across multiple organ systems. Its portfolio includes three assets targeting key fibrosis pathways, underpinned by state-of-the-art omics technology. The company also holds access to one of the largest single-cell human liver disease datasets in the world, accelerating precision drug discovery and development. With Sofinnova's €165M Biovelocita II fund, Forth Tx is poised for rapid growth, leveraging world-class expertise in translational medicine and biotechnology, from the vibrant research hubs of Edinburgh and Cambridge. Professor Henderson, Chair of Tissue Repair and Regeneration at the University of Edinburgh, said: "Launching Forth Tx through Sofinnova's biotech accelerator has allowed us to translate years of our multiomics-driven research into precision therapies that we hope will transform patients' lives. Fibrosis is an area of huge unmet medical need, and I'm delighted to be working with Alex and the Sofinnova team, as well as OCC, to deliver potent, new treatments for patients with fibrosis." Alex Leech, CEO of Forth Tx and Partner at Sofinnova Partners, added: "Forth Tx is breaking new ground in fibrosis therapeutics, combining world-class science with a capital-efficient, precision driven approach. I'm excited to be working with Neil and the University of Edinburgh team on this mission." Forth Tx is set to lead the way in fibrosis research and anti-fibrotic therapeutic design, harnessing next-generation, precision-driven approaches that promise to change the treatment landscape. About Forth Therapeutics Forth Therapeutics (Forth Tx) is a biotechnology company dedicated to advancing precision treatments for fibrosis. The company combines multi-omic insights, unrivalled access to data, and targeted therapies to address major unmet medical needs in fibrosis. Spun out of the University of Edinburgh and backed by Sofinnova Partners, Forth Tx is on a mission to bring transformative therapies to patients worldwide. For more information, please visit: About Sofinnova Partners Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners manages over €4 billion in assets. For more information, please visit: About Old College Capital Old College Capital (OCC) is the University of Edinburgh's venture investment fund. OCC manages Edinburgh's early-stage investment activities and shareholdings; supporting exciting ideas and technologies emerging from the University. OCC is part of Edinburgh Innovations, the University of Edinburgh's commercialisation service. View source version on Contacts Forth Tx Alex Leech Chief Executive Officeraleech@ Sofinnova Partners Bommy Lee Head of Communicationsblee@ +33 (0) 6 47 71 38 11 Sign in to access your portfolio
Yahoo
18-03-2025
- Business
- Yahoo
Sofinnova Partners Exceeds Target With €165M Biotech Acceleration Fund, Europe's Largest, With Strong Pharma Support
Biovelocita II attracts robust support from leading pharmaceutical companies, including Amgen, Bristol Myers Squibb, and Pfizer Ventures The fund has already screened over 300 projects and made several investments into new companies to catalyze transformative innovation in biotechnology PARIS, March 18, 2025--(BUSINESS WIRE)--Sofinnova Partners ("Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the final close of Sofinnova Biovelocita II. The fund has exceeded its target, successfully raising €165M, with substantial backing from the top global pharmaceutical companies, including Amgen, Bristol Myers Squibb, and Pfizer Ventures. This milestone marks a significant expansion of Sofinnova's biotech acceleration strategy, extending beyond Italy to include France, the United Kingdom, and Denmark, with ambitions to further reach additional European countries in the future. Since its launch, the fund has screened over 300 projects and made several key investments into new companies across Europe driving cutting-edge innovation in biotechnology. Among the newly established companies are BioClec, focused on breakthrough therapies for Alzheimer's disease; Forth Therapeutics, a spin-out of the University of Edinburgh, which is advancing next-generation precision therapeutics for fibrosis; and Signadori Bio, a novel cell therapy platform, developed from research at the Gustave Roussy Institute. Graziano Seghezzi, Managing Partner of Sofinnova Partners, said: "Building on the success of Biovelocita I in Italy, we have now developed a pan-European strategy and assembled a world class team to create and manage companies across the European biotech ecosystem. The strong response from our pharmaceutical partners and the fact that we exceeded our fundraising target underscore the demand for such an approach. This achievement highlights our commitment to fostering biotech innovation, supporting visionary entrepreneurs, and shaping the future of healthcare." Led by Partners Gabriella Camboni, Matthieu Coutet, Alex Leech and Zhizhong Joel Yao, Sofinnova Biovelocita II stands as the largest Pan-European biotech accelerator. It is dedicated to creating, building, and managing the next generation of biotech startups. The Sofinnova Biovelocita strategy offers scientific founders a comprehensive, hands-on framework, combining direct management, financial support, and access to Sofinnova's extensive infrastructure and network. This approach builds on more than a decade of expertise in startup acceleration, in biotech and medtech, which has already been instrumental in creating pioneering life sciences ventures. With several promising companies already established, Sofinnova Partners is set to unveil more innovative startups, continuing to shape the future of biotechnology. About Sofinnova PartnersSofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners manages over €4 billion in assets. For more information, please visit: View source version on Contacts Sofinnova Partners Bommy Lee Head of Communicationsblee@ +33 (0) 6 47 71 38 11 Media inquiries United Kingdom Optimum Strategic CommunicationsHana Maliksofinnova@ +44 (0) 20 3922 0900 France Strategies&Image (S&I)Anne +33 (0) 6 03 35 92 05 Italy Havas PR MilanPierluigi +39 (0) 392 77 999 33
